Who
Richard van den Broek
Director
Company insider
Files Form 4 as: Director, Pulse Biosciences; Director, Corvus Pharmaceuticals; Director, PhaseBio Pharmaceuticals; Director, Celldex Therapeutics; Director, Special Diversified Opportunities; Director, Pharmacyclics; Director, Response Genetics.
In numbers
- Trades disclosed
- 124
- Buys
- 2
- Sells
- 10
- Bought
- $169K
- Sold
- $13.9M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 12 Mar 2008
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —8,423 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —8,423 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 15 Aug 2025filed 19 Aug 2025 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 8 Apr 2025filed 9 Apr 2025 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Jun 2024filed 24 Jun 2024 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 6 Jun 2024filed 24 Jun 2024 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —11,649 at $0.00 | filing |
| 25 May 2023filed 6 Jun 2023 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 25 May 2023filed 6 Jun 2023 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —28,487 at $0.00 | filing |
| 19 May 2023filed 19 May 2023 | PhaseBio Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 19 May 2023filed 19 May 2023 | PhaseBio Pharmaceuticals | SEC FORM 4 Code A | —3,750 | filing |
| 19 May 2022filed 23 May 2022 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 May 2022filed 23 May 2022 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —79,206 at $0.00 | filing |
| 19 May 2022filed 20 May 2022 | PhaseBio Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 19 May 2022filed 20 May 2022 | PhaseBio Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 3 Jun 2021filed 4 Jun 2021 | PhaseBio Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 20 May 2021filed 21 May 2021 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.